Members of the FDA’s Pulmonary-Allergy Drugs Advisory Committee agreed 16-1 that the first-ever inhaled combination of two already-approved asthma drugs would benefit adults, but they declined to recommend it for teens (9-8) and children age four to 12 (16-1).
Source: Drug Industry Daily